Cellectar Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 4, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 4, 2026
CLRB$1.25+8.7%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements
FINANCIAL STATEMENTS
INDEX TO FINANCIAL STATEMENTS FOR CELLECTAR BIOSCIENCES, INC.
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (Deloitte & Touche LLP, Morristown, New Jersey, PCAOB ID No. 34) | 71 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | 74 |
| Consolidated Statements of Operations for the Years Ended December 31, 2025 and 2024 | 75 |
| Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Years Ended December 31, 2025 and 2024 | 76 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2025 and 2024 | 77 |
| Notes to Consolidated Financial Statements | 78 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.